Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone for newly diagnosed AL amyloidosis.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Amyloidosis | Phase 2 | Status: NOT_YET_RECRUITING